EP Patent

EP2187742B1 — (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol derivatives for use in the treatment of diabetes

Assigned to Theracos Sub LLC · Expires 2017-10-25 · 9y expired

What this patent protects

Patent listed against Brenzavvy.

Drugs covered by this patent

Patent Metadata

Patent number
EP2187742B1
Jurisdiction
EP
Classification
—
Expires
2017-10-25
Drug substance claim
No
Drug product claim
No
Assignee
Theracos Sub LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.